A Study to Assess Safety, Tolerability, and Pharmacokinetics of CC-92480 Formulations in Healthy Adult Participants

NCT ID: NCT04839809

Last Updated: 2021-12-10

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 40 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-01-19
• Study Completion Date: 2021-10-08

Brief Summary

This is a Phase 1 study that will be conducted in 2 parts. Participants may participate in 1 part only.

• Part 1 will be a randomized, double-blind, placebo-controlled, single ascending dose study to evaluate the safety, tolerability, and PK of CC-92480-02 (Formulation A) administered orally under fasted conditions in healthy adult participants.
• Part 2 will be a randomized, open-label, 2 × 4 crossover study (Periods 1, 2, 3, and 4) to evaluate the relative bioavailability (RBA) of Formulation A versus Formulation B under fasted conditions and explore safety, tolerability, and PK effects of food on Formulation A and Formulation B in healthy adult participants.

Conditions

Healthy Volunteers

Keywords

Healthy Volunteers; CC-92480; Pharmacokinetics

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

CC-92480-02 (Formulation A) with Placebo

CC-92480-02 (Formulation A) or matching placebo to be administered orally under fasted conditions.

Group Type: EXPERIMENTAL

CC-92480

Intervention Type: DRUG

Oral

Placebo

Intervention Type: OTHER

Oral

CC-92480 (Formulation B)- fasted condition

A single oral dose of CC-92480 (Formulation B) administered under fasted conditions.

Group Type: EXPERIMENTAL

CC-92480

Intervention Type: DRUG

Oral

CC-92480-02 (Formulation A) - fasted condition

A single oral dose of CC-92480-02 (Formulation A) administered under fasted conditions.

Group Type: EXPERIMENTAL

CC-92480

Intervention Type: DRUG

Oral

CC-92480 (Formulation B) - Low-fat meal

A single oral dose of CC-92480 (Formulation B) administered under fed conditions (low-fat meal).

Group Type: EXPERIMENTAL

CC-92480

Intervention Type: DRUG

Oral

CC-92480-02 (Formulation A) - high-fat meal

A single oral dose of CC-92480-02 (Formulation A) administered under fed conditions (high-fat meal).

Group Type: EXPERIMENTAL

CC-92480

Intervention Type: DRUG

Oral

Interventions

CC-92480

Oral

Intervention Type: DRUG

Placebo

Oral

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

Participants must satisfy the following criteria to be enrolled in the study:

1. Must understand and voluntarily sign a written informed consent form (ICF) prior to any study-related assessments/procedures being conducted.

2. Healthy adult female of nonchildbearing potential or male of any race, between 18 to 55 years of age (inclusive) at the time of signing the ICF, and in good health as determined by the screening history and Physical examination (PE).

3. Agrees to abide by the requirements and restrictions outlined in the CC-92480 Pregnancy Prevention Plan for Participants in Clinical Trials.

4. For males:

a. Practice true abstinence (which must be reviewed on a monthly basis, as applicable) or agree to use a barrier contraception not made of natural (animal) membrane (eg, latex or polyurethane condoms are acceptable) when engaging in sexual activity with a female of childbearing potential (FCBP) while on study medication, and for at 3 months after the last dose of study medication even if he has undergone a successful vasectomy.

5. For females:

Female participants must have been surgically sterilized (hysterectomy or bilateral oophorectomy; proper documentation required) at least 6 months before screening or be postmenopausal (defined as 24 months without menses before screening, with a serum follicle-stimulation hormone (FSH) level of > 40 IU/L at screening.

6. Must have a body mass index between 18 and 33 kg/m2 (inclusive) at the time of signing the ICF.

7. Clinical laboratory test results must be within the respective reference ranges; or if not, the results be clinically insignificant according to the Investigator's medical judgment.

8. Participant must agree and be willing to consume a standard high-fat meal (which may contain gluten), for Part 2 participants only.

Exclusion Criteria

The presence of any of the following will exclude a participant from enrollment:

1. Female of childbearing potential, pregnant, or breastfeeding.

2. History of any clinically significant and relevant neurological, gastrointestinal (GI), renal, hepatic, cardiovascular, psychological, pulmonary, metabolic, endocrine, hematological, allergic disease, drug allergies, or other major disorders as determined by the Investigator.

3. History of severe (eg, anaphylactic, anaphylactoid, Stevens-Johnson, angioedematous) reaction to a drug, or adverse reactions to multiple drugs.

4. Use of any prescribed systemic or topical medication (including but not limited to analgesics, anesthetics, etc) within 28 days of the first dose administration.

5. Use of any nonprescribed systemic or topical medication (including vitamin/mineral supplements, and herbal medicines) within 14 days of the first dose administration.

6. Donation of blood or plasma within 8 weeks before the first dose administration to a blood bank or blood donation center.

7. History of drug abuse (as defined by the current version of the Diagnostic and Statistical Manual [DSM]) within 2 years before first dose administration, or positive drug screening test reflecting consumption of illicit drugs.

8. History of alcohol abuse (as defined by the current version of the DSM) within 2 years before first dose administration, or positive alcohol screen.

9. Known to have serum hepatitis or known to be a carrier of hepatitis B surface antigen (HBsAg) or hepatitis C antibody (HCV Ab), or have a reactive result to the test for human immunodeficiency virus (HIV) antibodies at screening.

10. Use of tobacco- or nicotine-containing products within 3 months prior to Day -1, as assessed by medical history and physical examination, or positive urine cotinine test at screening.

11. Vaccination within 30 days of first dose administration or plans to receive vaccination (live and attenuated) within 30 days after dosing.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Celgene

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Bristol-Myers Squibb

Role: STUDY_DIRECTOR

Bristol-Myers Squibb

Locations

PPD Phase 1 Clinic

Austin, Texas, United States

Countries

United States

Other Identifiers

CC-92480-CP-003

Identifier Type: -

Identifier Source: org_study_id